Kinase Inhibitors Market Key Drivers, Insights, Outlook, Overview, and Research Report 2024-2033

The kinase inhibitors global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Kinase Inhibitors Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size – The kinase inhibitors market size has grown strongly in recent years. It will grow from $58.49 billion in 2023 to $62.75 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of cancer, advancements in targeted therapy, rising healthcare expenditure, approval of new kinase inhibitors, and growing adoption of personalized medicine.

The kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $83.56 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to ongoing research and development activities, introduction of novel kinase inhibitors, expanding applications beyond oncology, increasing investment in biotechnology, and growing awareness about precision medicine. Major trends in the forecast period include expansion of precision oncology treatments, development of combination therapies, increasing focus on rare and hard-to-treat cancers, advancements in biomarker-driven drug development, and growing adoption of next-generation sequencing technologies.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Scope Of Kinase Inhibitors MarketThe Business Research Company’s reports encompass a wide range of information, including:

Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
Drivers: Examination of the key factors propelling market growth.
Trends: Identification of emerging trends and patterns shaping the market landscape.
Key Segments: Breakdown of the market into its primary segments and their respective performance.
Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
Macro Economic Factors: Assessment of broader economic elements impacting the market.

Kinase Inhibitors Market Overview

Market Drivers -The increase in instances of autoimmune diseases is expected to propel the growth of the kinase inhibitors market going forward. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. The growing prevalence of autoimmune diseases is due to changes in lifestyle and diet, environmental pollution, genetic predisposition, stress, microbial imbalances, and the increasing incidence of chronic diseases like obesity and diabetes. Kinase inhibitors provide therapeutic benefits for autoimmune diseases by modulating the immune system, reducing inflammation, and alleviating symptoms such as psoriatic and rheumatoid arthritis. For instance, in December 2022, according to the National Psoriasis Foundation, a US-based non-profit organization serving people with Psoriasis and psoriatic arthritis, Psoriasis affected more than 8 million people in America and 125 million individuals worldwide, or 2 to 3% of the population. Furthermore, in September 2022, according to the Centers for Disease Control and Prevention, a US-based national public health agency, Diabetes was diagnosed in 28.7 million people of all ages, or 8.7% of the US population, and 5.7% of all US individuals with confirmed Diabetes—or 1.6 million people aged 20 and older—reported having type 1 diabetes and requiring insulin. Therefore, the increase in instances of autoimmune diseases is driving the growth of the kinase inhibitors market.

Market Trends – Major companies operating in the kinase inhibitors market are developing selective tyrosine kinase 2 (TYK2) inhibitors to address unmet needs in treating autoimmune and inflammatory diseases. Selective tyrosine kinase 2 (TYK2) inhibitors help treat cancer by modulating immune responses and reducing inflammation, which can enhance the body’s ability to target and destroy cancer cells and create a less favorable environment for tumor growth. For instance, in September 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received approval of Sotyktu (deucravacitinib) by the U.S. Food and Drug Administration (FDA). Sotyktu is an oral selective tyrosine kinase 2 (TYK2) inhibitor designed to treat moderate-to-severe plaque psoriasis in adults who require systemic therapy or phototherapy. The introduction of Sotyktu represents a significant advancement in treating plaque psoriasis, offering a new option for patients who may not respond adequately to existing therapies.

The kinase inhibitors market covered in this report is segmented –

1) By Type: Tyrosine Kinase Inhibitors, Multikinase Inhibitors, mTOR Kinase Inhibitors, Other Types

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By Application: Oncology, Inflammatory Diseases

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Get an inside scoop of the kinase inhibitors market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15841&type=smp

Regional Insights – Asia-Pacific was the largest region in the kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies – Major companies operating in the kinase inhibitors market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Astellas Pharma Inc, Cipla Inc, Dr. Reddy’s Laboratories Ltd, Endo International Inc., Amneal Pharmaceuticals LLC, Lupin Limited, Exelixis Inc, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals Ltd, Hutchison China MediTech Limited, Akorn Incorporated, Ocular Therapeutix Inc., Sierra Oncology Inc

Table of Contents